Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
March 12, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and...
Revance to Add Angus C. Russell as Chairman to Its Board of Directors
March 05, 2014 08:00 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and...
Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
February 19, 2014 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care...
Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
February 11, 2014 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Announces Pricing of Initial Public Offering
February 05, 2014 21:15 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...